|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/15/21 Arcadia Biosciences, Inc. 10-Q 9/30/21 92:13M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.20M
2: EX-10.1 Material Contract HTML 38K
3: EX-10.2 Material Contract HTML 89K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 28K
14: R1 Document and Entity Information HTML 80K
15: R2 Condensed Consolidated Balance Sheets (Unaudited) HTML 136K
16: R3 Condensed Consolidated Balance Sheets HTML 34K
(Parenthetical) (Unaudited)
17: R4 Condensed Consolidated Statements of Operations HTML 127K
and Comprehensive Loss (Unaudited)
18: R5 Condensed Consolidated Statements of Stockholders' HTML 185K
Equity (Unaudited)
19: R6 Condensed Consolidated Statements of Cash Flows HTML 176K
(Unaudited)
20: R7 Description of Business and Basis of Presentation HTML 53K
21: R8 Recent Accounting Pronouncements HTML 44K
22: R9 Inventory HTML 49K
23: R10 Property and Equipment, Net HTML 70K
24: R11 Investments and Fair Value Instruments HTML 299K
25: R12 Industrial Seed Innovations Acquisition HTML 55K
26: R13 Arcadia Wellness Acquisition HTML 114K
27: R14 Intangible Assets, Net HTML 130K
28: R15 Consolidated Joint Venture HTML 35K
29: R16 Collaborative Arrangements HTML 31K
30: R17 Leases HTML 127K
31: R18 Equity Financing HTML 65K
32: R19 Warrants HTML 301K
33: R20 Stock-Based Compensation and Employee Stock HTML 133K
Purchase Program
34: R21 Debt HTML 56K
35: R22 Income Taxes HTML 37K
36: R23 Commitment and Contingencies HTML 43K
37: R24 Net Loss per Share HTML 59K
38: R25 Related-Party Transactions HTML 38K
39: R26 Subsequent Events HTML 29K
40: R27 Description of Business and Basis of Presentation HTML 55K
(Policies)
41: R28 Inventory (Tables) HTML 45K
42: R29 Property and Equipment, Net (Tables) HTML 63K
43: R30 Investments and Fair Value Instruments (Tables) HTML 299K
44: R31 Industrial Seed Innovations Acquisition (Tables) HTML 62K
45: R32 Arcadia Wellness Acquisition (Tables) HTML 115K
46: R33 Intangible Assets, Net (Tables) HTML 130K
47: R34 Leases (Tables) HTML 118K
48: R35 Warrants (Tables) HTML 286K
49: R36 Stock-Based Compensation and Employee Stock HTML 109K
Purchase Program (Tables)
50: R37 Debt (Tables) HTML 42K
51: R38 Net Loss per Share (Tables) HTML 57K
52: R39 Description of Business and Basis of Presentation HTML 68K
- Additional Information (Detail)
53: R40 Recent Accounting Pronouncements - Additional HTML 53K
Information (Detail)
54: R41 Inventory - Additional Information (Detail) HTML 28K
55: R42 Inventory - Summary of Inventories (Detail) HTML 32K
56: R43 Property and Equipment, Net - Summary of Property HTML 47K
and Equipment, Net (Detail)
57: R44 Property and Equipment, Net - Additional HTML 36K
Information (Detail)
58: R45 Investments and Fair Value Instruments - HTML 30K
Additional Information (Detail)
59: R46 Investments and Fair Value Instruments - Summary HTML 39K
of Amortized Cost and Fair Value of Investment
Securities Portfolio (Detail)
60: R47 Investments and Fair Value Instruments - Summary HTML 39K
of Fair Value of Investments Securities (Detail)
61: R48 Investments and Fair Value Instruments - Summary HTML 61K
of Warrant Liabilities Measured and Recorded on
Recurring Basis using Black-Scholes Model (Detail)
62: R49 Investments and Fair Value Instruments - Summary HTML 50K
of Changes in Fair Value and Other Adjustments of
Liabilities (Detail)
63: R50 Industrial Seed Innovations Acquisition - HTML 73K
Additional Information (Detail)
64: R51 Industrial Seed Innovations Acquisition - Schedule HTML 40K
of Preliminary Allocation of the Purchase Price of
ISI Assets Acquired Based on Fair Values (Detail)
65: R52 Arcadia Wellness Acquisition - Additional HTML 89K
Information (Detail)
66: R53 Arcadia Wellness Acquisition - Schedule of HTML 49K
Preliminary Allocation of the Purchase Price of
Assets Acquired Based on Fair Values (Detail)
67: R54 Arcadia Wellness Acquisition - Schedule of HTML 41K
Unaudited Pro-forma Condensed Consolidated Results
of Operations (Detail)
68: R55 Intangible Assets, Net - Schedule of Intangible HTML 48K
Assets, Net (Detail)
69: R56 Intangible Assets, Net - Schedule of Intangible HTML 28K
Assets, Net (Parenthetical) (Details)
70: R57 Intangible Assets, Net - Additional Information HTML 32K
(Detail)
71: R58 Intangible Assets, Net - Schedule of Future HTML 44K
Amortization of Intellectual Property and Customer
Lists (Detail)
72: R59 Consolidated Joint Venture - Additional HTML 44K
Information (Detail)
73: R60 Collaborative Arrangements - Additional HTML 29K
Information (Detail)
74: R61 Leases - Additional Information (Detail) HTML 53K
75: R62 Leases - Schedule of Leases (Detail) HTML 64K
76: R63 Equity Financing - Additional Information (Detail) HTML 137K
77: R64 Warrants - Additional Information (Detail) HTML 87K
78: R65 Warrants - Summary of Warrants Issued to Purchase HTML 93K
Common Stock (Detail)
79: R66 Warrants - Summary of Key Terms and Activity of HTML 54K
Liability Classified Common Stock Warrants
(Detail)
80: R67 Stock-Based Compensation and Employee Stock HTML 91K
Purchase Program - Additional Information (Detail)
81: R68 Stock-Based Compensation and Employee Stock HTML 60K
Purchase Program - Summary of Activity Under Stock
Incentive Plans (Detail)
82: R69 Stock-Based Compensation and Employee Stock HTML 35K
Purchase Program - Weighted-Average Fair Value
Assumption of Stock Option Awards (Detail)
83: R70 Debt - Additional Information (Detail) HTML 72K
84: R71 Debt - Schedule of Maturities of Current and HTML 38K
Noncurrent Debt (Detail)
85: R72 Income Taxes - Additional Information (Detail) HTML 33K
86: R73 Commitments and Contingencies - Additional HTML 65K
Information (Detail)
87: R74 Net Loss per Share - Summary of Securities Not HTML 35K
Included in Diluted Per Share Calculations
(Detail)
88: R75 Related-Party Transactions - Additional HTML 54K
Information (Detail)
90: XML IDEA XML File -- Filing Summary XML 168K
13: XML XBRL Instance -- rkda-20210930_htm XML 3.64M
89: EXCEL IDEA Workbook of Financial Reports XLSX 117K
10: EX-101.CAL XBRL Calculations -- rkda-20210930_cal XML 214K
12: EX-101.DEF XBRL Definitions -- rkda-20210930_def XML 979K
9: EX-101.LAB XBRL Labels -- rkda-20210930_lab XML 1.59M
11: EX-101.PRE XBRL Presentations -- rkda-20210930_pre XML 1.25M
8: EX-101.SCH XBRL Schema -- rkda-20210930 XSD 238K
91: JSON XBRL Instance as JSON Data -- MetaLinks 441± 700K
92: ZIP XBRL Zipped Folder -- 0000950170-21-004634-xbrl Zip 312K
| EX-10.1 |
Exhibit 10.1
Dear Laura:
This letter sets forth the terms of your employment as Chief Marketing Officer of Arcadia Biosciences, Inc. (the “Company”), which will commence on July 12, 2021 (the “Effective Date”). The terms set forth below shall be effective as of the Effective Date.
Reporting and Base Salary. You will report to the President and Chief Executive Officer, Matthew Plavan. This is a full-time exempt position for which your annual base salary rate shall be $250,000. You will work remotely from your home office in Dallas, TX, but you will be expected to travel to the Company’s corporate offices in Davis, CA, or the Company’s manufacturing location in Chatsworth, CA, from time to time as requested by the Company’s President and Chief Executive Officer.
Sign-on Bonus. In addition to your base salary, your offer also includes a sign-on bonus of $50,000; $25,000 payable with your first paycheck, and $25,000 payable on January 1, 2022. You must be employed with the company and in good standing to receive your sign-on bonus payment for that date. All bonus payments are subject to standard withholdings.
Bonus Compensation. In addition to your base salary and sign-on bonus, you will be eligible for an annual incentive cash award, as determined by the Company. Your annual incentive cash bonus shall have a target equal to 40% of your base salary as of the Effective Date, prorated for the portion of year during which you are employed by the Company. The target bonus and its components, the Company performance objectives, and your individual objectives shall be determined each year by the Compensation Committee of the Board of Directors (the “Compensation Committee”).
Severance & CIC Agreement. You will have the benefits set forth in a (3-Month) Severance Agreement and (1-year) Change-in-Control Agreement, pending Arcadia Board of Director’s approval, between you and the Company to be executed on the Effective Date.
Equity Awards. Concurrent with the commencement of your employment with the Company, and as an inducement to accept employment with the Company, you will be granted an option to purchase shares of common stock of the Company (“Company Common Stock”) as follows, under the terms and conditions of a Non-Qualified Stock Option Agreement (an “Option”):
Strike Price* |
Number of Shares |
FMV |
75,000 |
* FMV = the price of a share of RKDA common stock at close of market on the date of grant, which will be the Effective Date.
Your Option shall vest and become exercisable in accordance with the schedule below:
202 Cousteau Place Ÿ Suite 105 Ÿ Davis, CA 95618 Ÿ Tel: 530-756-7077Ÿ Fax: 530-756-7027 Ÿ Web: www.arcadiabio.com
The Company may grant additional equity awards to you from time to time, which will be subject to the terms of the applicable equity compensation plan or arrangement in effect at the time of grant. The Compensation Committee will determine in its discretion whether you will be granted any such equity awards and the terms and conditions of any such awards in accordance with the terms of any applicable equity plan. You should be aware that you may incur federal and state income taxes as a result of your receipt, or the vesting of any equity compensation awards, and it shall be your responsibility to pay any such applicable taxes.
You are also eligible to participate in the Company’s Employee Stock Purchase Program (ESPP) per the terms and conditions of the ESPP plan.
Other Benefits. You are eligible for all Company benefits as described in the Employee Handbook and in various Company policies. Your coverage for medical, dental and vision insurance will become effective on September 1, 2021. If needed, the Company will reimburse you for any COBRA-related costs to bridge your healthcare benefits coverage to September 1, 2021.
Your PTO accrual of 7.0769 hours per pay period (23 days annually) will begin with your first paycheck. You are granted an additional 8.0 hours (1 day) of PTO each year as part of your offer of employment.
In accordance with the Federal Immigration Reform and Control Act of 1986, the Company is required to have an Employment Eligibility Verification Form I-9 on file for you. On your first day of employment, we will ask you to provide identification needed to complete the form. Arcadia uses E-Verify and will provide the Social Security Administration and, if necessary, the Department of Homeland Security information from your Form I-9 to confirm that you are authorized to work in the United States.
Your employment is “at-will,” which means that either you or the Company may terminate the employment relationship at any time for any reason or for no reason. This at-will relationship may not be modified by any oral or implied agreement.
This letter, the Severance Agreement and the Confidentiality and Invention Assignment Agreement executed on the Effective Date, and any policies that the Company may adopt from time to time constitute the entire agreement relating to the terms of your employment with the Company you and is contingent upon successful completion of all background checks. If all the above terms and conditions meet with your approval, please sign this letter and return it to me at your earliest convenience.
If you should have any questions, please feel free to call me.
Sincerely,
Matthew Plavan
President & CEO
ACCEPTED AND ACKNOWLEDED BY:
/s/ Laura Pitlik
Date
202 Cousteau Place Ÿ Suite 105 Ÿ Davis, CA 95618 Ÿ Tel: 530-756-7077Ÿ Fax: 530-756-7027 Ÿ Web: www.arcadiabio.com
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 7/31/25 | ||||
| 8/31/22 | ||||
| 1/1/22 | ||||
| Filed on: | 11/15/21 | 8-K | ||
| For Period end: | 9/30/21 | |||
| 9/1/21 | ||||
| 7/12/21 | 3, 4, 8-K | |||
| 6/26/21 | ||||
| 6/24/21 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/13/23 Arcadia Biosciences, Inc. 10-K/A 12/31/22 12:2M Donnelley … Solutions/FA 3/30/23 Arcadia Biosciences, Inc. 10-K 12/31/22 110:18M Donnelley … Solutions/FA 9/27/22 Arcadia Biosciences, Inc. S-1 6:672K ActiveDisclosure/FA 3/31/22 Arcadia Biosciences, Inc. 10-K 12/31/21 114:19M Donnelley … Solutions/FA 2/11/22 Arcadia Biosciences, Inc. 424B3 1:811K Donnelley … Solutions/FA 1/28/22 Arcadia Biosciences, Inc. S-1 6:1.1M ActiveDisclosure/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/07/21 Arcadia Biosciences, Inc. 8-K:5,9 9/03/21 12:655K Donnelley … Solutions/FA |